21
Mitchell E Reff, William S Kloetzer, Takehiko Nakamura: Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics. Biogen Idec MA, Sterne Kessler Goldstein & Fox P L L C, April 13, 2010: US07695940

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practic ...


22

23
Mitchell E Reff, William S Kloetzer, Takehiko Nakamura: Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics. Biogen Idec, Pillsbury Winthrop, March 10, 2005: US20050054833-A1

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practic ...


24
Mitchell E Reff, William S Kloetzer, Takehiko Nakamura: Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics. Biogen Idec MA, Pillsbury Winthrop Shaw Pittman, March 22, 2007: US20070065434-A1

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practic ...


25
Mitchell E Reff, William S Kloetzer, Takehiko Nakamura: Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics. Biogen Idec MA, Pillsbury Winthrop Shaw Pittman, March 22, 2007: US20070065435-A1

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practic ...


26
Mitchell E Reff: Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same. Pillsbury Winthrop, February 20, 2003: US20030036113-A1

Disclosed herein are fully impaired consensus Kozak sequences which are most typically used with dominant selectable markers of transcriptional cassettes which are a part of an expression vector, These vectors are most typically utilized in the expression of proteins in mammalian expression systems. ...


27
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Pillsbury Winthrop, May 22, 2003: US20030095963-A1

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


28
Mitchell E Reff, William S Kloetzer, Takehiko Nakamura: Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics. IDEC Pharmaceutical Corporation, Pillsbury Winthrop, March 27, 2003: US20030059424-A1

Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practic ...


29
Mitchell E Reff, Eric Ailor, Michael J Betenbaugh, Bruno Figueroa, Marie Hardwick: Inhibition of apoptosis process and improvement of cell performance. IDEC Pharmaceuticals Corporation, Pillsbury Winthrop, April 3, 2003: US20030064510-A1

The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by ...


30
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Pillsbury Winthrop, August 7, 2003: US20030147885-A1

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...